Current Headlines

  1. New Long-Term Data Presented At WCPGHAN 2016 Show Rapid And Sustained Improvements In Important Markers Of Liver Injury And Lipid Abnormalities In Children And Adults With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma (sebelipase alfa)

    Alexion Pharmaceuticals, Inc. announced recently that researchers presented new long-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma (sebelipase alfa) in children and adults with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease

  2. Pall Life Sciences Extends The Range Of Continuous, Single-Use Technologies To Improve Speed And Quality Of Biopharmaceutical Production

    Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the launch of breakthrough technologies that for the first time enable integrated, process-scale continuous production of biotherapies in single-use formats

  3. Theranexus Has Obtained An Orphan Drug Designation From The FDA For THN102 In The Treatment Of Narcolepsy

    Theranexus, a clinical-stage biopharmaceutical company, announced today that it’s most advanced drug candidate, THN102, has received an Orphan Drug Designation (ODD) from the American regulatory agency, the FDA, for the treatment of narcolepsy, a rare and highly debilitating sleep/wake disorder

  4. twoXAR Collaborates With Researchers At Mount Sinai To Advance New Medicines For Diabetic Nephropathy

    twoXAR, Inc., a company dedicated to improving health through computation, recently announced its collaboration with researchers from the Icahn School of Medicine at Mount Sinai to further validate computational approaches in early-stage drug discovery

  5. Recursion Pharmaceuticals Raises $13M To Discover New Drugs Using Artificial Intelligence

    Recursion Pharmaceuticals recently announced its $12.9M Series A round of funding, led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild Basin Investments, and several prominent angel investors

  6. CohBar Advances First-In-Class Mitochondria Based Therapeutic To IND-Enabling Activities

    CohBar, Inc. , an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) for age-related diseases, recently announced the selection of two analogs from the company’s MOTS-c program for advancement into IND-enabling activities

  7. Enanta Pharmaceuticals Announces AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

    Enanta Pharmaceuticals, Inc.,, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for AbbVie’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1 (GT1), including previous therapy with an NS5A inhibitor and/or protease inhibitor

  8. Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy

    Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company (“Catabasis”), and Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics (“Sarepta”), recently announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD)

  9. Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-Alcoholic Steatohepatitis (NASH)

    Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced that it has initiated a Phase 1 clinical study and has begun dosing healthy adults with EDP-305, Enanta’s lead farnesoid X receptor (FXR) agonist under development to treat patients with NASH

  10. Zymeworks And Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement And Bi-Specific Antibody Collaboration

    Zymeworks Inc., a clinical-stage biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics including bi-specific antibodies and drug conjugates for the treatment of cancer, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced recently that they have entered into a cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products